- Page 3/4
- Next Page
COMMENT
Medical device ETF? Likes medical devices, and they've significantly outperformed the other sub-sectors. Tend to be less susceptible to the political noise. Great earnings growth. But if we see an improvement to some of the other sub-sectors, we could see them underperform the others. So have a diversified portfolio in that space.
HOLD
A long-term play. Low EPS growth of about 3.5-4%. Very large company. Don't have a lot of drugs that have exposure over 10%, except Prevnar. Not his favourite growth position. Diversity of assets. Need to do some M&A. Stable dividend. Only paying 15x. You can hold on to this.
biotechnology
pharmaceutical
COMMENT
Demonstrates how binary risk can happen in individual securities. Big driver recently has been failure in an Alzheimer's study. Had to shut the study down, which caught the market by surprise. Likes it, though risk in this stock is high, with a relatively high rate of return. For all large cap biotech, make sure you have at least a couple of positions.
biotechnology
pharmaceutical
WATCH
Likes it. One of better growth profiles for large cap pharma. Exceptional job building out the pipeline in oncology and diabetes. Cardiac drug seems like becoming the standard of care. Some hiccups, but the market gave them a pass. 14-15% EPS growth. 17x next year's earnings. Make sure the launches are on track next quarter.
biotechnology
pharmaceutical
HOLD
Large cap, diversified. Long life assets. They need to find growth and acquisitions. Healthy distribution. Analysts question the dividend. Low growth profile. A strong hold, but be cognizant that they need to buy companies to fill out the pipeline and keep up the dividend growth.
biotechnology
pharmaceutical
HOLD
Likes 2-year time horizon. A stellar performer. Executing on top and bottom line. An example of how margins should be. Couple of new products are coming out, and one of best organic growth profiles in the sector. This quarter was the first hiccup in a long time, but the market gave them a pass. He'll give them another quarter to prove themselves.
biotechnology
pharmaceutical
